Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Grows By 55.1%

Atyr PHARMA INC (NASDAQ:ATYR) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,660,000 shares, an increase of 55.1% from the October 15th total of 1,070,000 shares. Based on an average trading volume of 761,100 shares, the days-to-cover ratio is currently 2.2 days. Currently, 2.0% of the shares of the company are short sold.

Atyr PHARMA Stock Down 8.9 %

ATYR traded down $0.29 during trading on Friday, reaching $2.91. 1,386,422 shares of the company were exchanged, compared to its average volume of 574,810. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The stock has a market cap of $243.85 million, a P/E ratio of -3.10 and a beta of 1.10. Atyr PHARMA has a 12-month low of $1.09 and a 12-month high of $3.80. The company has a 50-day simple moving average of $2.47.

Atyr PHARMA (NASDAQ:ATYR) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Equities analysts forecast that Atyr PHARMA will post -0.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ATYR. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, October 29th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Atyr PHARMA in a report on Wednesday, August 14th. Jefferies Financial Group started coverage on shares of Atyr PHARMA in a research note on Thursday, September 5th. They issued a “buy” rating and a $9.00 target price for the company. Finally, Wells Fargo & Company began coverage on shares of Atyr PHARMA in a research note on Friday, October 4th. They set an “overweight” rating and a $17.00 price target on the stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.